THE SIGNIFICANCE OF ALK REARRANGEMENT IN SELECTED ADVANCED NON-SMALL CELL LUNG CANCER: ALK EXPRESSION PROVIDES INSIGHTS INTO ALK TARGET THERAPY

被引：0
|
作者：
Zhang, Ningning [1 ,2 ]
Shi, Yuankai [1 ,2 ]
Ma, Li [1 ,2 ]
Hao, Xuezhi [1 ,2 ]
Lin, Dongmei [2 ,3 ]
Han, Xiaohong [1 ,2 ]
Liu, Yutao [1 ,2 ]
Wang, Lin [1 ,2 ]
Yuan, Zheng [2 ,3 ]
Yang, Sheng [1 ,2 ]
机构：
[1] Chinese Acad Med Sci, Canc Inst Hosp, Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China
[2] Peking Union Med Coll, Beijing, Peoples R China
[3] Chinese Acad Med Sci, Canc Inst Hosp, Dept Pathol, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
Alk rearrangement; non-small cell lung cancer; ALK expression; Crizotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.11-038
引用
收藏
页码：S612 / S612
页数：1
相关论文
共 50 条
  • [31] Analysis of ALK Rearrangement Non-Small Cell Lung Cancer Cell Blocks from Pleural Effusion
    Xu, C.
    Wang, W.
    Zhuang, W.
    Chen, G.
    Tian, Y.
    Xu, J.
    Fang, M.
    Lv, T.
    Song, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S978 - S978
  • [32] ALK inhibitors in non-small cell lung cancer: the latest evidence and developments
    Sullivan, Ivana
    Planchard, David
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2016, 8 (01) : 32 - 47
  • [33] Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer
    Xiang, Yan
    Zhang, Shiyu
    Fang, Xiaoxu
    Jiang, Yingying
    Fang, Tingwen
    Liu, Jinwen
    Lu, Kaihua
    CURRENT ONCOLOGY, 2022, 29 (10) : 7816 - 7831
  • [34] Future options for ALK-positive non-small cell lung cancer
    Iacono, Daniela
    Chiari, Rita
    Metro, Giulio
    Bennati, Chiara
    Bellezza, Guido
    Cenci, Matteo
    Ricciuti, Biagio
    Sidoni, Angelo
    Baglivo, Sara
    Minotti, Vincenzo
    Crino, Lucio
    LUNG CANCER, 2015, 87 (03) : 211 - 219
  • [35] Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer
    Bland, Abigail R.
    Bower, Rebekah L.
    Nimick, Mhairi
    Hawkins, Bill C.
    Rosengren, Rhonda J.
    Ashton, John C.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 865
  • [36] ALK-rearrangement in non-small-cell lung cancer (NSCLC)
    Du, Xue
    Shao, Yun
    Qin, Hai-Feng
    Tai, Yan-Hong
    Gao, Hong-Jun
    THORACIC CANCER, 2018, 9 (04) : 423 - 430
  • [37] Clinical observation of crizotinib in the treatment of ALK-positive advanced non-small cell lung cancer
    Deng, Huiyan
    Li, Bin
    Li, Lina
    Peng, Jingcui
    Lv, Tongshuai
    Liu, Yueping
    Ding, Cuimin
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (12)
  • [38] Treatment of ALK-Positive Non-Small Cell Lung Cancer
    Bang, Yung-Jue
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (10) : 1201 - 1204
  • [39] Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors
    Singh, Abhay
    Chen, Hongbin
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 6615 - 6628
  • [40] Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer
    Sullivan, Ivana
    Planchard, David
    FUTURE ONCOLOGY, 2016, 12 (07) : 945 - 961
12345